Extrait

Primary objective of the Phase 1 part determination of the recommended Phase 2 dose of LY2603618. Primary objective of the Phase 2 part are Determination if the progression-free survival (PFS) time, from the date of randomization to induction therapy, is improved for patients with Stage IV nonsquamous NSCLC when LY2603618 is added to the first-line therapy of 4 cycles of pemetrexed and cisplatin followed by maintenance therapy of pemetrexed with or without LY2603618 Due to the dosing regimen changes, subgroup analysis on patients who were treated per JMMG Amendemnt (c) will be performed for PFS.

Critère d'inclusion

• • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin is deemed to be appropriate. • Solid tumors with no other standard therapeutic option with ≤2 previous systemic chemotherapies for their disease and a maximum of 6 cycles of alkylating agents in all previous therapy settings

Liens

• euctr
• ictrp